Drug dosing in patients with low body weight

Clicks: 14
ID: 329465
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #210 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: To highlight important considerations when designing dosing regimens for patients with low body weight. SUMMARY: Pharmacokinetic alterations that occur in patients with low body weight could lead to inappropriate drug concentrations and adverse effects if standard doses for patients with normal body habitus are used. In contrast to information on drug dosing in patients with obesity, there is a dearth of publications concerning drug dosing in patients with low body weight. Weight descriptors available for dosing patients with low body weight are the same as those used in obese patients but are not as well studied. However, there are general considerations regarding weight descriptors for weight-based drug dosing that are similar for patients with low or excess weight such as the lack of demonstrated usefulness of ideal body weight. The results of investigations that are available for drug dosing in patients with low body weight are primarily limited to antimicrobial and anticoagulant agents, which have well established forms of therapeutic drug monitoring or laboratory monitoring parameters. Of note, the antimicrobials and anticoagulants studied in patients with low body weight tend to be hydrophilic drugs that are eliminated by the kidneys. This has implications for pharmacokinetic parameters, including volume of distribution and clearance that may not be applicable for more lipophilic agents. There is little information on lipophilic drugs with larger volumes of distribution and often non-renal mechanisms of clearance. CONCLUSION: There is a paucity of information regarding drug dosing in patients with low body weight. The limited information suggests substantial variability in pharmacokinetic outcomes and clinical outcomes with standard doses in low weight patients. Nevertheless, this group should be considered a "special population" where individualized dosing approaches should be sought. More research is needed in this area particularly with respect to size descriptors useful for weight-based drug dosing and for lipophilic drugs that are not amenable to some form of therapeutic drug monitoring.
Reference Key
openalex_W7214040083 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brian L. Erstad, Jeffrey F. Barletta
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag292
URL
https://doi.org/10.1093/ajhp/zxag292
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.